A new vaccine to enhance immune response against HPV-related cancers
Official title: Highly stable mini-circRNA vaccine with maximally activated and long-lasting T cells for HPV-related cancer combination immunotherapy
Funded at Ampedrna Biosciences LLC · NIH-10921006 · Data updated 2026-11-12
This study is working on a new mini-vaccine that helps your immune system better fight cancers linked to HPV, like anal and cervical cancers, aiming to make treatments more effective and safer for patients.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ampedrna Biosciences LLC NIH-funded |
| Lab location | 1 site (Richmond, United States) |
| Project start | August 1, 2024 |
| Project end | July 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $398,823 |
| NIH project number | 1R43CA287530-01A1 |
| Project ID | NIH-10921006 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with HPV-related cancers, particularly those who may not have responded well to existing treatments.
✕Less likely to help
Patients with non-HPV related cancers or those who have already undergone extensive treatment may not benefit from this research.
What this research studies
This research focuses on developing a mini-circRNA vaccine aimed at enhancing the immune response specifically against cancers related to human papillomavirus (HPV), such as anal and cervical cancers. The approach involves creating a vaccine that can stimulate T cells to recognize and attack cancer cells more effectively. By utilizing innovative immunotherapy techniques, the goal is to improve the efficacy of existing treatments and provide a safer, more cost-effective option for patients. This vaccine could potentially be used at various stages of cancer, making it a versatile treatment option.
Why it matters
Potential benefit: If successful, this research could lead to a more effective vaccine that significantly improves the immune response against HPV-related cancers, potentially reducing cancer incidence and mortality.
How similar studies have gone: While there have been successful immunotherapy approaches in cancer treatment, this specific mini-circRNA vaccine approach is relatively novel and has not been extensively tested.
Where this research is happening
-
Ampedrna Biosciences LLC
Richmond, United States Active
Researchers
- Principal investigator: Parry, Gordon — Ampedrna Biosciences LLC
- Study coordinator: Parry, Gordon
Related research
Other NIH-funded projects on the same topics.
-
Boosting immune response to fight cancer
This study is exploring a new way to help your immune system better fight cancer by tweaking certain cells in your body, and it aims to improve treatment for people with advanced cancer.
-
A center focused on immunotherapy for pediatric cancers.
This study is exploring new ways to use the body's immune system to fight childhood cancers, aiming to create better treatments for kids whose cancers haven't responded well to standard therapies.
-
Algorithms to find HLA-E neoantigens for cancer immunotherapy
Aims to develop computer methods to discover tumor-specific targets presented by HLA-E to guide new T cell therapies for cancer.
-
Immunotherapy for glioblastoma: advancing treatment and understanding
A patient-friendly summary of a grant exploring new immune-based treatments for glioblastoma to improve options for people affected by this brain cancer.
-
How CRISPR-based gene activation could shape immunotherapy responses in clear cell cancers
A research project at Stanford is using CRISPR-based gene activation to understand why some clear cell ovarian and kidney cancers respond to immunotherapy while others do not.
-
Hybrid biomaterial system to boost immunotherapy for rheumatoid arthritis
A new, patient-facing immunotherapy approach uses specialized particles to retrain the immune system to calm RA in adults.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.